{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:13:37Z","timestamp":1793391217936,"version":"4.5.0"},"reference-count":104,"publisher":"Georg Thieme Verlag KG","issue":"04","funder":[{"name":"Anniversary Fund of the Austrian National Bank","award":["18500"],"award-info":[{"award-number":["18500"]}]},{"name":"Medical-Scientific Fund of the Mayor of the Federal Capital Vienna","award":["20023"],"award-info":[{"award-number":["20023"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with an unexplained mild to moderate bleeding tendency are diagnosed with bleeding disorder of unknown cause (BDUC), a classification reached after ruling out other mild to moderate bleeding disorders (MBD) including von Willebrand disease (VWD), platelet function defects (PFDs), coagulation factor deficiencies (CFDs), and non-hemostatic causes for bleeding. This review outlines our diagnostic approach to BDUC, a diagnosis of exclusion, drawing on current guidelines and insights from the Vienna Bleeding Biobank (VIBB). According to guidelines, we diagnose VWD based on VWF antigen and\/or activity levels \u226450\u2009IU\/dL, with repeated VWF testing if VWF levels are &lt;80\u2009IU\/dL. This has been introduced in our clinical routine after our findings of diagnostically relevant fluctuations of VWF levels in a high proportion of MBD patients. PFDs are identified through repeated abnormalities in light transmission aggregometry (LTA), flow cytometric mepacrine fluorescence, and glycoprotein expression analysis. Nevertheless, we experience diagnostic challenges with regard to reproducibility and unspecific alterations of LTA. For factor (F) VIII and FIX deficiency, a cutoff of 50% is utilized to ensure detection of mild hemophilia A or B. We apply established cutoffs for other rare CFD being aware that these do not clearly reflect the causal role of the bleeding tendency. Investigations into very rare bleeding disorders due to hyperfibrinolysis or increase in natural anticoagulants are limited to cases with a notable family history or distinct bleeding phenotypes considering cost-effectiveness. While the pathogenesis of BDUC remains unknown, further explorations of this intriguing area may reveal new mechanisms and therapeutic targets.<\/jats:p>","DOI":"10.1055\/a-2263-5706","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T19:50:57Z","timestamp":1709063457000},"page":"287-297","source":"Crossref","is-referenced-by-count":25,"title":["Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion"],"prefix":"10.1055","volume":"44","author":[{"given":"Dino","family":"Mehic","sequence":"additional","affiliation":[{"name":"Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Gebhart","sequence":"additional","affiliation":[{"name":"Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pabinger","sequence":"additional","affiliation":[{"name":"Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1097\/HS9.0000000000000286","article-title":"Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: an EHA consensus report","volume":"3","author":"F Rodeghiero","year":"2019","journal-title":"HemaSphere"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/jth.14363","article-title":"Diagnostic challenges of inherited mild bleeding disorders: a bait for poorly explored clinical and basic research","volume":"17","author":"D Mezzano","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref3","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"F Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1538-7836.2005.01663.x","article-title":"The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study","volume":"3","author":"F Rodeghiero","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/hae.13422","article-title":"High proportion of patients with bleeding of unknown cause in persons with a mild-to-moderate bleeding tendency: results from the Vienna Bleeding Biobank (VIBB)","volume":"24","author":"J Gebhart","year":"2018","journal-title":"Haemophilia"},{"issue":"19","key":"ref6","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood.2020010038","article-title":"How I treat bleeding disorder of unknown cause","volume":"138","author":"R I Baker","year":"2021","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2020.04.023","article-title":"The discriminatory power of bleeding assessment tools in adult patients with a mild to moderate bleeding tendency","volume":"78","author":"J Gebhart","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"08","key":"ref8","doi-asserted-by":"crossref","first-page":"102242","DOI":"10.1016\/j.rpth.2023.102242","article-title":"Investigating patients for bleeding disorders when most of the \u201cusual\u201d ones have been ruled out","volume":"7","author":"D Mehic","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/jth.14529","article-title":"Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause","volume":"17","author":"S Hofer","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref10","first-page":"e106","article-title":"Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: a prospective cohort study","volume":"26","author":"C SB Veen","year":"2020","journal-title":"Haemophilia"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/jth.15524","article-title":"Thrombin generation measured by two platforms in patients with a bleeding tendency: comment","volume":"19","author":"W Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jtha.2023.03.006","article-title":"Risk factors for future bleeding in patients with mild bleeding disorders: longitudinal data from the Vienna Bleeding Biobank","volume":"21","author":"D Mehic","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1055\/s-0041-1726344","article-title":"Outcome of surgical interventions and deliveries in patients with bleeding of unknown cause: an observational study","volume":"121","author":"C SB Veen","year":"2021","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1111\/jth.15871","article-title":"Outcomes and management of pregnancy in women with bleeding disorder of unknown cause","volume":"20","author":"D Castle","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"102176","DOI":"10.1016\/j.rpth.2023.102176","article-title":"Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank","volume":"7","author":"D Mehic","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1111\/jth.15492","article-title":"Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders","volume":"19","author":"W Thomas","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jtha.2023.03.025","article-title":"The natural history of bleeding disorder of unknown cause","volume":"21","author":"W Thomas","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"20","key":"ref18","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1182\/bloodadvances.2020002452","article-title":"Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause","volume":"4","author":"D Mehic","year":"2020","journal-title":"Blood Adv"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"e12511","DOI":"10.1002\/rth2.12511","article-title":"Fibrinolysis and bleeding of unknown cause","volume":"5","author":"D Mehic","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/hae.14356","article-title":"Natural anticoagulants: a missing link in mild to moderate bleeding tendencies","volume":"27","author":"D Mehic","year":"2021","journal-title":"Haemophilia"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"P D James","year":"2021","journal-title":"Blood Adv"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2009-10-249102","article-title":"Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor","volume":"116","author":"V H Flood","year":"2010","journal-title":"Blood"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjh.16681","article-title":"New developments in von Willebrand disease","volume":"191","author":"H Fogarty","year":"2020","journal-title":"Br J Haematol"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/jth.14319","article-title":"Clinically relevant differences between assays for von Willebrand factor activity","volume":"16","author":"J Boender","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12380","article-title":"Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies","volume":"20","author":"J Costa-Pinto","year":"2014","journal-title":"Haemophilia"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1111\/hae.12937","article-title":"Comparison of von Willebrand factor (VWF) activity levels determined by HemosIL AcuStar assay and HemosIL LIA assay with ristocetin cofactor assay by aggregometry","volume":"22","author":"S Sagheer","year":"2016","journal-title":"Haemophilia"},{"issue":"07","key":"ref27","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/jth.14145","article-title":"A comparative analysis of different automated von Willebrand factor glycoprotein Ib-binding activity assays in well typed von Willebrand disease patients","volume":"16","author":"I Vangenechten","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"18","key":"ref28","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1182\/blood-2012-12-471672","article-title":"No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation","volume":"121","author":"V H Flood","year":"2013","journal-title":"Blood"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtha.2022.11.042","article-title":"Beyond the guidelines: how we approach challenging scenarios in the diagnosis and management of von Willebrand disease","volume":"21","author":"M Y Abou-Ismail","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.exger.2007.06.014","article-title":"Hemostasis factors and aging","volume":"43","author":"D Mari","year":"2008","journal-title":"Exp Gerontol"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Y V Sanders","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bjh.15277","article-title":"Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease","volume":"182","author":"F Atiq","year":"2018","journal-title":"Br J Haematol"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"J C Gill","year":"1987","journal-title":"Blood"},{"issue":"20","key":"ref34","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1182\/blood-2015-10-673681","article-title":"Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States","volume":"127","author":"V H Flood","year":"2016","journal-title":"Blood"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1373\/clinchem.2016.261248","article-title":"Biological variation of hemostasis variables in thrombosis and bleeding: consequences for performance specifications","volume":"62","author":"M PM de Maat","year":"2016","journal-title":"Clin Chem"},{"issue":"S 05","key":"ref36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2516.2010.02305.x","article-title":"Quality issues in laboratory haemostasis","volume":"16","author":"F E Preston","year":"2010","journal-title":"Haemophilia"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jtha.2023.09.010","article-title":"The necessity of repeat testing for von Willebrand disease in adult patients with mild to moderate bleeding disorders","volume":"22","author":"D Mehic","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1111\/jth.14591","article-title":"Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients","volume":"17","author":"B S Doshi","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"e12513","DOI":"10.1002\/rth2.12513","article-title":"Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease","volume":"5","author":"M C Brown","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"102165","DOI":"10.1016\/j.rpth.2023.102165","article-title":"Letter in response to Othman & Favaloro \u201cComparison of two ways of performing ristocetin-induced platelet agglutination (RIPA) mixing study for diagnosis of type 2B VWD\u201d","volume":"7","author":"R Soleimani","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"100286","DOI":"10.1016\/j.rpth.2023.100286","article-title":"Comparison of 2 ways of performing ristocetin-induced platelet agglutination mixing study for diagnosis of type 2B von Willebrand disease. Response to the publication of Soleimani et al","volume":"7","author":"E J Favaloro","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"e12635","DOI":"10.1002\/rth2.12635","article-title":"2B von Willebrand disease diagnosis: considerations reflecting on 2021 multisociety guidelines","volume":"5","author":"M Othman","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"23","key":"ref43","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood.2018891192","article-title":"Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders","volume":"134","author":"K Downes","year":"2019","journal-title":"Blood"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/s-0035-1570078","article-title":"Inherited platelet function disorders: algorithms for phenotypic and genetic investigation","volume":"42","author":"P Gresele","year":"2016","journal-title":"Semin Thromb Hemost"},{"issue":"S 01","key":"ref45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/ijlh.12539","article-title":"Current and emerging approaches for evaluating platelet disorders","volume":"38","author":"G Podda","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jth.12792","article-title":"Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH","volume":"13","author":"P Gresele","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/a-2099-3266","article-title":"State-of-the-art targeted high-throughput sequencing for detecting inherited platelet disorders","volume":"43","author":"J Gebetsberger","year":"2023","journal-title":"Hamostaseologie"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1097\/HS9.0000000000000601","article-title":"The EHA research roadmap: platelet disorders","volume":"5","author":"C Balduini","year":"2021","journal-title":"HemaSphere"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2022.11.021","article-title":"Usefulness of global tests of primary hemostasis in the initial screening of mild\/moderate bleeding disorders for orienting towards von Willebrand disease or inherited platelet functions disorders","volume":"221","author":"A Baccolo","year":"2023","journal-title":"Thromb Res"},{"issue":"17","key":"ref50","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1182\/blood.2019004776","article-title":"Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome","volume":"136","author":"M C Sims","year":"2020","journal-title":"Blood"},{"issue":"06","key":"ref51","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jth.12231","article-title":"Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC\/ISTH","volume":"11","author":"M Cattaneo","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"23","key":"ref52","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood-2010-05-286534","article-title":"Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p","volume":"116","author":"M Gunay-Aygun","year":"2010","journal-title":"Blood"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ijlh.12801","article-title":"Electron microscopy examination of platelet whole mount preparations to quantitate platelet dense granule numbers: Implications for diagnosing suspected platelet function disorders due to dense granule deficiency","volume":"40","author":"J G Brunet","year":"2018","journal-title":"Int J Lab Hematol"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/09537104.2018.1476682","article-title":"Diagnostic laboratory standardization and validation of platelet transmission electron microscopy","volume":"29","author":"D Chen","year":"2018","journal-title":"Platelets"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2141.1995.tb08901.x","article-title":"Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry","volume":"89","author":"N Gordon","year":"1995","journal-title":"Br J Haematol"},{"issue":"02","key":"ref56","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2141.1995.tb03315.x","article-title":"A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents","volume":"89","author":"J E Wall","year":"1995","journal-title":"Br J Haematol"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/jth.14698","article-title":"Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency","volume":"18","author":"I van Asten","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0039-1687889","article-title":"Molecular diagnosis of inherited coagulation and bleeding disorders","volume":"45","author":"J M Bastida","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"ref59","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1111\/jth.15459","article-title":"GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis","volume":"19","author":"K Megy","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref60","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/jth.14993","article-title":"Clinical management, ethics and informed consent related to multi-gene panel-based high throughput sequencing testing for platelet disorders: communication from the SSC of the ISTH","volume":"18","author":"K Downes","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1538-7836.2006.01771.x","article-title":"Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function","volume":"4","author":"C P Hayward","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref62","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-0029-1220785","article-title":"The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays","volume":"35","author":"D Mezzano","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2516.2011.02733.x","article-title":"The PFA-100 \u00ae does not predict delta-granule platelet storage pool deficiencies","volume":"18","author":"J L Sladky","year":"2012","journal-title":"Haemophilia"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/j.1538-7836.2007.02752.x","article-title":"Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time","volume":"5","author":"G M Podda","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1055\/s-0040-1721502","article-title":"Utility of the platelet function analyzer in patients with suspected platelet function disorders: diagnostic accuracy study","volume":"4","author":"J Kaufmann","year":"2020","journal-title":"TH Open"},{"issue":"S 01","key":"ref66","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2023-185756","article-title":"Utility of the platelet function analyzer (PFA-100) in patients with bleeding disorder of unknown cause","volume":"142","author":"D Mehic","year":"2023","journal-title":"Blood"},{"issue":"09","key":"ref67","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1016\/j.jtha.2023.05.027","article-title":"Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology","volume":"21","author":"M C Alessi","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/jth.15687","article-title":"Low COAT platelets are frequent in patients with bleeding disorders of unknown cause (BDUC) and can be enhanced by DDAVP","volume":"20","author":"A Segot","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1055\/a-2080-6602","article-title":"Treatment of inherited platelet disorders: current status and future options","volume":"43","author":"C Bargehr","year":"2023","journal-title":"Hamostaseologie"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-0038-1675354","article-title":"Epidemiology and treatment of patients with haemophilia in Austria - update from the Austrian Haemophilia Registry","volume":"39","author":"J Rejt\u0151","year":"2019","journal-title":"Hamostaseologie"},{"issue":"05","key":"ref71","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/jth.14770","article-title":"Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A","volume":"18","author":"J Rejt\u0151","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref72","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1538-7836.2012.04844.x","article-title":"Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity","volume":"10","author":"F Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"13","key":"ref73","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","article-title":"Rare bleeding disorders: diagnosis and treatment","volume":"125","author":"R Palla","year":"2015","journal-title":"Blood"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2516.2008.01667.x","article-title":"Factor XI deficiency","volume":"14","author":"K Gomez","year":"2008","journal-title":"Haemophilia"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jtha.2022.10.005","article-title":"Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency","volume":"21","author":"S E Reitsma","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"B A Yi","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref77","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2014-10-604553","article-title":"Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation","volume":"125","author":"Y Dargaud","year":"2015","journal-title":"Blood"},{"issue":"12","key":"ref78","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood-2014-02-557538","article-title":"A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop)","volume":"124","author":"J Langdown","year":"2014","journal-title":"Blood"},{"issue":"09","key":"ref79","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/jth.14990","article-title":"A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency","volume":"18","author":"S K Westbury","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref80","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/hae.14433","article-title":"Thrombomodulin in patients with mild to moderate bleeding tendency","volume":"27","author":"D Mehic","year":"2021","journal-title":"Haemophilia"},{"issue":"09","key":"ref81","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1172\/JCI69091","article-title":"Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPI\u03b1","volume":"123","author":"L M Vincent","year":"2013","journal-title":"J Clin Invest"},{"issue":"11","key":"ref82","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2014-08-592733","article-title":"A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function","volume":"125","author":"M LR Cunha","year":"2015","journal-title":"Blood"},{"issue":"S 01","key":"ref83","first-page":"366","article-title":"Factor V Atlanta: a novel mutation in the F5 gene reveals potential new Cis-acting elements involved in regulating FV-short and TFPI Levels","volume":"130","author":"K L Zimowski","year":"2017","journal-title":"Blood"},{"issue":"07","key":"ref84","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/jth.13665","article-title":"Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitor\u03b1, and protein S","volume":"15","author":"B Dahlb\u00e4ck","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ijlh.12508","article-title":"Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders","volume":"38","author":"B Dahlb\u00e4ck","year":"2016","journal-title":"Int J Lab Hematol"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/bloodadvances.2020003464","article-title":"Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency","volume":"5","author":"D Mehic","year":"2021","journal-title":"Blood Adv"},{"issue":"02","key":"ref87","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1172\/JCI112346","article-title":"Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf","volume":"77","author":"C F Scott","year":"1986","journal-title":"J Clin Invest"},{"issue":"12","key":"ref88","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJM198309223091203","article-title":"Mutation of antitrypsin to antithrombin. Alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder","volume":"309","author":"M C Owen","year":"1983","journal-title":"N Engl J Med"},{"issue":"10","key":"ref89","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1172\/JCI133780","article-title":"A coagulation defect arising from heterozygous premature termination of tissue factor","volume":"130","author":"S Schulman","year":"2020","journal-title":"J Clin Invest"},{"issue":"08","key":"ref90","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/jth.14160","article-title":"Hemorrhagic disorders of fibrinolysis: a clinical review","volume":"16","author":"J L Saes","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00277-016-2893-6","article-title":"Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause","volume":"96","author":"J Gebhart","year":"2017","journal-title":"Ann Hematol"},{"issue":"02","key":"ref92","doi-asserted-by":"crossref","first-page":"e12681","DOI":"10.1002\/rth2.12681","article-title":"Fibrinolytic assays in bleeding of unknown cause: improvement in diagnostic yield","volume":"6","author":"L LFG Valke","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12959-022-00435-6","article-title":"Laboratory evaluation of a new integrative assay to phenotype plasma fibrinolytic system","volume":"20","author":"M Bareille","year":"2022","journal-title":"Thromb J"},{"issue":"01","key":"ref94","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.transci.2018.02.020","article-title":"A new assay for global fibrinolysis capacity (GFC): investigating a critical system regulating hemostasis and thrombosis and other extravascular functions","volume":"57","author":"J Amiral","year":"2018","journal-title":"Transfus Apheresis Sci"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00508-017-1194-y","article-title":"Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis","volume":"129","author":"I Pabinger","year":"2017","journal-title":"Wien Klin Wochenschr"},{"issue":"06","key":"ref96","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/hae.14174","article-title":"Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management","volume":"26","author":"W Thomas","year":"2020","journal-title":"Haemophilia"},{"issue":"06","key":"ref97","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/j.ajkd.2006.03.036","article-title":"Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy","volume":"47","author":"C Sucker","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"09","key":"ref98","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective","volume":"103","author":"A Kritharis","year":"2018","journal-title":"Haematologica"},{"issue":"07","key":"ref99","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.jtha.2023.04.004","article-title":"Characterization of bleeding symptoms in Ehlers-Danlos syndrome","volume":"21","author":"M Kumskova","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/10245330600667591","article-title":"Hemostatic changes in thyroid diseases: haemostasis and thrombosis","volume":"11","author":"M Franchini","year":"2006","journal-title":"Hematology"},{"issue":"08","key":"ref101","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1055\/s-0032-1328881","article-title":"Drugs that affect platelet function","volume":"38","author":"R E Scharf","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.thromres.2005.07.025","article-title":"Vitamins and minerals that affect hemostasis and antithrombotic therapies","volume":"117","author":"R Rebecca Couris","year":"2005","journal-title":"Thromb Res"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0002-8703(88)90648-5","article-title":"Cigarette smoking and hemostatic function","volume":"115","author":"G A FitzGerald","year":"1988","journal-title":"Am Heart J"},{"issue":"49","key":"ref104","doi-asserted-by":"crossref","first-page":"e13432","DOI":"10.1097\/MD.0000000000013432","article-title":"Dark chocolate modulates platelet function with a mechanism mediated by Flavan-3-Ol metabolites","volume":"97","author":"M Montagnana","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2263-5706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:45:49Z","timestamp":1730807149000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2263-5706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":104,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2024,8,16]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2263-5706","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}